Experience with Eslicarbazepine Acetate Treatment at a Pediatric Epilepsy Center

IF 0.2 Q4 PEDIATRICS

Journal of Pediatric Epilepsy Pub Date : 2020-12-07 DOI:10.1055/s-0040-1719160

A. Tanritanir, Xiaofan Wang, T. Loddenkemper

{"title":"Experience with Eslicarbazepine Acetate Treatment at a Pediatric Epilepsy Center","authors":"A. Tanritanir, Xiaofan Wang, T. Loddenkemper","doi":"10.1055/s-0040-1719160","DOIUrl":null,"url":null,"abstract":"Abstract Eslicarbazepine acetate (ESL) is a novel, once-daily antiseizure medication. We evaluated the efficacy and safety profile of ESL treatment in epilepsy patients at a single tertiary epilepsy center. In this retrospective observational study, we included 32 patients with pharmacologically intractable epilepsy receiving ESL at Boston Children's Hospital from June 2014 to June 2018. We assessed treatment outcome in terms of efficacy and tolerability at first and last follow-up (f/u). Median age was 17 (interquartile range: 10.8–20.7; range: 6.5–36) years. Twelve (37.5%) patients, including three with seizure freedom, were responders at last f/u. Eleven patients discontinued ESL due to seizure worsening (9, 28%), adverse events (AEs) (2, 6%) or both (4, 12%). Responders showed greater seizure reduction at last f/u with fewer AEs as compared with nonresponders. Ten (31%) patients developed AEs, the most common being sleep problems (5, 15%). One-year retention rate with ESL treatment was 54%. In conclusion, ESL had a good response rate in patients with pharmacologically intractable epilepsy, with about one-third of patients developing AEs.","PeriodicalId":42559,"journal":{"name":"Journal of Pediatric Epilepsy","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2020-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Epilepsy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0040-1719160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 3

Abstract

Abstract Eslicarbazepine acetate (ESL) is a novel, once-daily antiseizure medication. We evaluated the efficacy and safety profile of ESL treatment in epilepsy patients at a single tertiary epilepsy center. In this retrospective observational study, we included 32 patients with pharmacologically intractable epilepsy receiving ESL at Boston Children's Hospital from June 2014 to June 2018. We assessed treatment outcome in terms of efficacy and tolerability at first and last follow-up (f/u). Median age was 17 (interquartile range: 10.8–20.7; range: 6.5–36) years. Twelve (37.5%) patients, including three with seizure freedom, were responders at last f/u. Eleven patients discontinued ESL due to seizure worsening (9, 28%), adverse events (AEs) (2, 6%) or both (4, 12%). Responders showed greater seizure reduction at last f/u with fewer AEs as compared with nonresponders. Ten (31%) patients developed AEs, the most common being sleep problems (5, 15%). One-year retention rate with ESL treatment was 54%. In conclusion, ESL had a good response rate in patients with pharmacologically intractable epilepsy, with about one-third of patients developing AEs.

查看原文本刊更多论文

在儿童癫痫中心应用醋酸埃斯卡巴西平治疗的经验

醋酸埃斯卡巴西平(ESL)是一种新型的每日一次的抗癫痫药物。我们在单一三级癫痫中心评估ESL治疗癫痫患者的疗效和安全性。在这项回顾性观察性研究中，我们纳入了2014年6月至2018年6月在波士顿儿童医院接受ESL治疗的32例药理学难治性癫痫患者。在第一次和最后一次随访时，我们根据疗效和耐受性(f/u)评估治疗结果。中位年龄为17岁(四分位数范围:10.8-20.7;年龄范围:6.5-36岁。12例(37.5%)患者(包括3例癫痫发作自由患者)在最后f/u时有应答。11例患者因癫痫发作恶化(9.28%)、不良事件(2.6%)或两者兼而有之(4.12%)而停用ESL。与无反应者相比，有反应者在最后f/u时癫痫发作减少更大，ae更少。10例(31%)患者发生不良反应，最常见的是睡眠问题(5.15%)。ESL治疗的1年保留率为54%。综上所述，ESL在药理学上难治性癫痫患者中具有良好的应答率，约三分之一的患者发生ae。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pediatric Epilepsy PEDIATRICS-

自引率

0.00%

发文量

期刊介绍： The Journal of Pediatric Epilepsy is an English multidisciplinary peer-reviewed international journal publishing articles on all topics related to epilepsy and seizure disorders, epilepsy surgery, neurology, neurosurgery, and neuropsychology in childhood. These topics include the basic sciences related to the condition itself, the differential diagnosis, natural history, and epidemiology of seizures, and the investigation and practical management of epilepsy (including drug treatment, neurosurgery and non-medical and behavioral treatments). Use of model organisms and in vitro techniques relevant to epilepsy are also acceptable. Journal of Pediatric Epilepsy provides an in-depth update on new subjects and current comprehensive coverage of the latest techniques used in the diagnosis and treatment of childhood epilepsy.